Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.72 |
| ▸ | POLB | P06746 | 2/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.63 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.50 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26984449 | 0.85 | TDP1 (0.58) | CYP1A2POLBCYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL31547600 | 0.84 | CYP1A2 (0.70) | CYP1A2POLBCYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL11009450 | 0.82 | ALDH1A1 (0.69) | CYP1A2POLBCYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL31467164 | 0.82 | ALDH1A1 (0.69) | CYP1A2POLBCYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL31547646 | 0.81 | CYP1A2 (0.67) | CYP1A2POLBCYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL31467098 | 0.81 | CYP1A2 (0.67) | CYP1A2POLBCYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL26984402 | 0.81 | CYP1A2 (0.67) | CYP1A2POLBCYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL30830216 | 0.81 | CYP1A2 (0.67) | CYP1A2POLBCYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL26984437 | 0.81 | CYP1A2 (0.67) | CYP1A2POLBCYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL13611512 | 0.81 | ALDH1A1 (0.48) | CYP1A2POLBCYP2C9CYP2C19L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188040-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS INC | 2025-06-12 | — | — | US | disclosed |
| EP-4551555-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | Vividion Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| WO-2025073792-A1 | WRN INHIBITORY COMPOUNDS | FORX THERAPEUTICS AG (CH) | 2025-04-10 | — | — | WO | disclosed |
| CN-119677716-A | Pharmaceutical compositions comprising WRN helicase inhibitors | 维维迪恩医疗公司 | 2025-03-21 | — | — | CN | disclosed |
| US-12187685-B2 | Pharmaceutical compositions comprising WRN helicase inhibitors | VIVIDION THERAPEUTICS, INC. | 2025-01-07 | — | — | US | disclosed |
| US-20240140915-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. | 2024-05-02 | — | — | US | disclosed |
| US-20240067612-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240067612-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240067612-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. | 2024-02-29 | — | — | US | disclosed |
| WO-2024010782-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| WO-2024010782-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067612-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | RECQL, BLM, WRN | CYP1A2 3573/4885POLB 71/4885CYP2C9 3104/4885 |
| US-20240140915-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | RECQL, BLM, WRN | CYP1A2 3573/4885POLB 71/4885CYP2C9 3104/4885 |
| US-12187685-B2 | Pharmaceutical compositions comprising WRN helicase inhibitors | RECQL, BLM, WRN | CYP1A2 3573/4885POLB 71/4885CYP2C9 3104/4885 |
| US-20250188040-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | RECQL, BLM, WRN | CYP1A2 3573/4885POLB 71/4885CYP2C9 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.